With $50M up front in metabolic deal, Lilly tightens ties with Regor

Months after its Asia-focused venture arm participated in Shanghai-based Regor’s series B round, Lilly is partnering with the Chinese biotech for access to its IP and discovery expertise to develop treatments for metabolic disorders.

For $50 million in upfront cash and equity,  Eli Lilly and Co. (NYSE:LLY) will gain a license to IP from Regor Therapeutics Group as well as ex-Greater China rights to therapeutics stemming from the collaboration. Lilly said it hopes the partnership will yield treatments for obesity and diabetes; the deal includes $1.5 billion in development and commercial milestones, plus royalties up to the low double-digits...